R
Ross C. Donehower
Researcher at Johns Hopkins University
Publications - 233
Citations - 32588
Ross C. Donehower is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pharmacokinetics & Chemotherapy. The author has an hindex of 72, co-authored 229 publications receiving 28457 citations. Previous affiliations of Ross C. Donehower include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le,Dung T. Le,Jennifer N. Durham,Jennifer N. Durham,Kellie N. Smith,Hao Wang,Bjarne Bartlett,Bjarne Bartlett,Laveet K. Aulakh,Laveet K. Aulakh,Steve Lu,Steve Lu,Holly Kemberling,Cara Wilt,Brandon Luber,Fay Wong,Fay Wong,Nilofer S. Azad,Agnieszka A. Rucki,Daniel A. Laheru,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Tim F. Greten,Austin G. Duffy,Kristen K. Ciombor,Aleksandra Eyring,Bao H. Lam,Andrew K. Joe,S. Peter Kang,Matthias Holdhoff,Ludmila Danilova,Leslie Cope,Christian F. Meyer,Shibin Zhou,Shibin Zhou,Richard M. Goldberg,Deborah K. Armstrong,Katherine M. Bever,Amanda N. Fader,Janis M. Taube,Franck Housseau,David Spetzler,Nianqing Xiao,Drew M. Pardoll,Nickolas Papadopoulos,Nickolas Papadopoulos,Kenneth W. Kinzler,Kenneth W. Kinzler,James R. Eshleman,Bert Vogelstein,Bert Vogelstein,Robert A. Anders,Robert A. Anders,Luis A. Diaz,Luis A. Diaz +57 more
TL;DR: Evaluating the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1).
Journal ArticleDOI
PD-1 blockade in tumors with mismatch repair deficiency.
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Nilofer S. Azad,Daniel A. Laheru,Ross C. Donehower,Brandon Luber,Todd S. Crocenzi,George A. Fisher,Steve M Duffy,James J. Lee,Minori Koshiji,James R. Eshleman,Robert A. Anders,Bert Vogelstein,Luis A. Diaz +19 more
TL;DR: MM status predicts clinical benefit of immune checkpoint blockade with pembrolizumab, and high total somatic mutation loads were associated with PFS.
Journal ArticleDOI
Hypersensitivity reactions from taxol.
Raymond B. Weiss,Ross C. Donehower,Peter H. Wiernik,T Ohnuma,R J Gralla,Donald L. Trump,J R Baker,D. A. Van Echo,D. D. Von Hoff,Brian Leyland-Jones +9 more
TL;DR: Hypersensitivity reactions to taxol have been one of the toxicities observed with administration of this drug and guidelines are provided to prevent or minimize such toxicity and treat reactions if they still occur.
Journal ArticleDOI
Taxol: A Novel Investigational Antimicrotubule Agent
TL;DR: Taxol's unique mechanism of action, its spectrum of preclinical antitumor activity, and tumor responses in early clinical trials have generated renewed interest in pursuing its development.